ALXO Research and Charts

ALXO - ALX Oncology Holdings Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-01-03)

Last 1.81	Change ⇑ +0.25 (+16.03%)	Volume 1,142,294
	Open 1.56	High 1.87	Low 1.56

8EMA (Daily) 1.69	40EMA (Daily) 1.64	50EMA (Daily) 1.70	STO (Daily) 40.381	MACD Hist (Daily) 0.013
8EMA (Weekly) 1.631	40EMA (Weekly) 4.47	50EMA (Weekly) 5.24	STO (Weekly) 43.227	MACD Hist (Weekly) 0.599


Company Profile
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company. The firm is focused on developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Its lead product candidate under development, ALX148, is a next-generation CD47 blocking therapeutic for the treatment of first-line head and neck cancer and second-line gastric/gastroesophageal junction cancer and breast cancer.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.